^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + APOBEC3B overexpression
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Oncol
    Title:

    APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder

    Excerpt:
    The combined survival analysis of A3B and CD274 showed that the group of patients with high expression of CD274 and A3B was found to have a significantly higher survival rate than the rest of the patient group (P < 0.047).
    DOI:
    10.1155/2022/6042334